|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 7272 WISCONSIN AVENUE |
Address2 | |
City | BETHESDA |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 3457-12
|
||||||||
|
6. House ID# 315500000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brian M. Meyer, Director, Government Affairs Division |
Date | 07/17/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code WAS
16. Specific lobbying issues
Communication with EPA regarding health care industry study on practices related to disposal of unused pharmaceuticals.
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Justine |
Coffey |
|
|
|
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Geralyn |
Trujillo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
FDA Appropriations FY10. Communication to White House Office on Health Care Reform. Support for HR 2891, Access to Frontline Health Care Act of 2009, all provisions. Support for S 245, Retooling the Healthcare Workforce for an Aging America Act of 2009. Letter urging funding for residency programs in America's Affordable Health Choices Act, HR 3200. Statement to Senate Finance Committee on Healthcare Reform Delivery Options and Coverage Options. Statement to Senate Finance Committee
on workforce. Statement to House Energy and Commece Committee on Health Reform. Letters to Senate Finance and Ways and Means Committees on residency funding. Communication with Congressional Budget Office on heatlh care reform. Communication with FDA regarding market withdrawal of morphine sulphate oral solution. Communicatin with FDA on Risk Evaluation and Mititgation Strategies for certain opioid drugs. Communication with NIOSH regarding additions and deltions to hazardous drug list. Communication with FDA regarding safety of acetaminophen-containing drug products.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Communication with CMS on Hospital Inpatient Prospective Payment System. Communication with Office of the National Coordinator on Health Information Technology regarding definition of "meaningful use."
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Communication with FDA and HHS regarding standards for securing the drug supply chain and the National Drug Code system. Communication with the Office of the National Coordinator regarding "Draft Use of Electronic Health Records in Clinical Research. Communication with Food and Drug Administration on evaluation of consumer medication information. Communication with Health Resources and Services Administration on National Quality Forum priorities and pharmacist residency training and workforce issues.
Comments to Office of the National Coordinator regarding health information technology extension program. Communication with Drug Enforcement Administration regarding implementation of Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Communication with Centers for Medicare and Medicaid Services regarding anticoagulation clinic billing issue.
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Drug Enforcement Administration (DEA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |